Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Targeting the vascular dysfunction: Potential treatments for preeclampsia.

Marshall SA, Cox AG, Parry LJ, Wallace EM.

Microcirculation. 2018 Dec 16:e12522. doi: 10.1111/micc.12522. [Epub ahead of print]

PMID:
30556222
2.

Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.

Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, Senadheera S, Illanes SE, Kaitu'u-Lino TJ, Tong S.

Am J Obstet Gynecol. 2016 Mar;214(3):356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019. Epub 2015 Dec 22.

PMID:
26721779
3.

Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.

Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, Parry L, Dilworth M, Renshall L, Brownfoot F, Hastie R, Tuohey L, Palmer K, Hirano T, Ikawa M, Kaitu'u-Lino T, Hannan NJ.

Hypertension. 2017 Mar;69(3):457-468. doi: 10.1161/HYPERTENSIONAHA.116.08408. Epub 2017 Jan 23. Erratum in: Hypertension. 2018 Apr;71(4):e11.

PMID:
28115513
4.

In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.

Holme AM, Roland MC, Henriksen T, Michelsen TM.

Am J Obstet Gynecol. 2016 Dec;215(6):782.e1-782.e9. doi: 10.1016/j.ajog.2016.07.056. Epub 2016 Aug 5.

PMID:
27503620
5.

Pre-eclampsia: clinical manifestations and molecular mechanisms.

Baumwell S, Karumanchi SA.

Nephron Clin Pract. 2007;106(2):c72-81. Epub 2007 Jun 6. Review.

PMID:
17570933
6.

The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).

Chaiworapongsa T, Romero R, Erez O, Tarca AL, Conde-Agudelo A, Chaemsaithong P, Kim CJ, Kim YM, Kim JS, Yoon BH, Hassan SS, Yeo L, Korzeniewski SJ.

Am J Obstet Gynecol. 2017 Dec;217(6):682.e1-682.e13. doi: 10.1016/j.ajog.2017.10.001. Epub 2017 Oct 13. Erratum in: Am J Obstet Gynecol. 2018 Feb 1;:.

7.

Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia.

Silasi M, Cohen B, Karumanchi SA, Rana S.

Obstet Gynecol Clin North Am. 2010 Jun;37(2):239-53. doi: 10.1016/j.ogc.2010.02.013. Review.

PMID:
20685551
8.

Preeclampsia: the role of angiogenic factors in its pathogenesis.

Wang A, Rana S, Karumanchi SA.

Physiology (Bethesda). 2009 Jun;24:147-58. doi: 10.1152/physiol.00043.2008. Review.

9.

Vascular biology of preeclampsia.

Myatt L, Webster RP.

J Thromb Haemost. 2009 Mar;7(3):375-84. doi: 10.1111/j.1538-7836.2008.03259.x. Review.

10.

The role of angiogenic factors in the management of preeclampsia.

Flint EJ, Cerdeira AS, Redman CW, Vatish M.

Acta Obstet Gynecol Scand. 2019 Jun;98(6):700-707. doi: 10.1111/aogs.13540. Epub 2019 Feb 22. Review.

PMID:
30667052
11.

Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia.

Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA.

Pediatr Res. 2005 May;57(5 Pt 2):1R-7R. Epub 2005 Apr 6. Review.

PMID:
15817508
12.

The role of angiogenic factors in pre-eclampsia.

Abimanyu B.

Pregnancy Hypertens. 2014 Jul;4(3):246. doi: 10.1016/j.preghy.2014.04.019. Epub 2014 Jul 9.

PMID:
26104650
13.

Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.

Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ.

Circulation. 2010 Aug 3;122(5):478-87. doi: 10.1161/CIRCULATIONAHA.109.895458. Epub 2010 Jul 19. Erratum in: Circulation. 2011 Sep 13;124(11):e302.

PMID:
20644016
14.

Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia.

Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, Hastie R, Onda K, Kaitu'u-Lino TJ.

Hypertension. 2015 Sep;66(3):687-97; discussion 445. doi: 10.1161/HYPERTENSIONAHA.115.05445. Epub 2015 Jul 27.

PMID:
26222708
15.

A longitudinal analysis of angiotensin II type 1 receptor antibody and angiogenic markers in pregnancy.

Aggarwal S, Sunderland N, Thornton C, Xu B, Hennessy A, Makris A.

Am J Obstet Gynecol. 2017 Feb;216(2):170.e1-170.e8. doi: 10.1016/j.ajog.2016.10.028. Epub 2016 Oct 26.

PMID:
27793555
16.

Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia.

Shah DA, Khalil RA.

Biochem Pharmacol. 2015 Jun 15;95(4):211-26. doi: 10.1016/j.bcp.2015.04.012. Epub 2015 Apr 24. Review.

17.

[New insights in the pathophysiology of preeclampsia and potential therapeutic implications].

Boulanger H, Flamant M.

Nephrol Ther. 2007 Dec;3(7):437-48. Epub 2007 Aug 29. Review. French.

PMID:
18047998
18.

Management of preeclampsia.

Dekker GA.

Pregnancy Hypertens. 2014 Jul;4(3):246-7. doi: 10.1016/j.preghy.2014.04.021. Epub 2014 Jul 9.

PMID:
26104648
19.
20.

Supplemental Content

Support Center